Lixisenatide for Fat Loss
Short-acting prandial GLP-1 agonist; sold as Adlyxin/Lyxumia by Sanofi.
Why Lixisenatide for fat loss?
Lixisenatide is an exendin-4 analog with a six-lysine C-terminal extension. Approved in the EU (2013, Lyxumia) and US (2016, Adlyxin) by Sanofi. Short half-life (~3h) makes it more effective for postprandial glucose than fasting glucose. ELIXA trial showed CV neutrality. Discontinued in the US in 2023 due to low uptake.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Lixisenatide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Modest weight loss
Reference dosing by bodyweight
Anchored to the most-cited research dose (10 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 6–8 mcg |
| 60–75 kg / 132–165 lb | 8–10 mcg |
| 75–90 kg / 165–198 lb | 9–13 mcg |
| 90–105 kg / 198–231 lb | 11–15 mcg |
| >105 kg / >231 lb | 13–17 mcg |
Side effects to weigh against fat loss benefit
- Nausea
- Hypoglycemia (with sulfonylureas)
- Injection-site reaction
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.